文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

(S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD).

作者信息

Lindsley Craig W

出版信息

ACS Chem Neurosci. 2010 Aug 18;1(8):530-1. doi: 10.1021/cn100070s.

DOI:10.1021/cn100070s
PMID:22778844
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3368682/
Abstract
摘要

相似文献

[1]
(S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD).

ACS Chem Neurosci. 2010-8-18

[2]
Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant.

Eur Neuropsychopharmacol. 2013-12-21

[3]
Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine.

Depress Anxiety. 2002

[4]
Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy.

World J Biol Psychiatry. 2015-10

[5]
Safety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term study.

J Clin Psychopharmacol. 2015-2

[6]
Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study.

J Clin Psychopharmacol. 2008-6

[7]
Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests.

Behav Brain Res. 2009-1-30

[8]
Similar activity of mecamylamine stereoisomers in vitro and in vivo.

Eur J Pharmacol. 2013-10-23

[9]
Mecamylamine (Targacept).

IDrugs. 2006-3

[10]
Nicotinic acetylcholine receptors as targets for antidepressants.

Mol Psychiatry. 2002

引用本文的文献

[1]
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.

Mol Psychiatry. 2015-7-7

[2]
Molecular interactions between mecamylamine enantiomers and the transmembrane domain of the human α4β2 nicotinic receptor.

Biochemistry. 2014-1-30

[3]
Similar activity of mecamylamine stereoisomers in vitro and in vivo.

Eur J Pharmacol. 2013-10-23

[4]
Citalopram versus other anti-depressive agents for depression.

Cochrane Database Syst Rev. 2012-7-11

[5]
Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond.

Physiol Behav. 2012-7-6

[6]
Functional brain imaging of nicotinic effects on higher cognitive processes.

Biochem Pharmacol. 2011-6-13

本文引用的文献

[1]
The top prescription drugs of 2009 in the US: CNS therapeutics rank among highest grossing.

ACS Chem Neurosci. 2010-6-16

[2]
TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity.

CNS Neurosci Ther. 2008

[3]
The economic burden of depression in the United States: how did it change between 1990 and 2000?

J Clin Psychiatry. 2003-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索